Company Overview of Catalent Pharma Solutions, Inc.
Catalent Pharma Solutions, Inc. provides development solutions and delivery technologies for drugs, biologics, and consumer health products. The company’s Development and Clinical Services segment offers manufacturing, packaging, storage, and inventory management services for drugs and biologics in clinical trials. This segment also provides analytical chemical and cell-based testing and scientific services; respiratory products formulation and manufacturing; regulatory consulting; and bioanalytical testing for biologic products. Its Oral Technologies segment offers oral delivery technologies, including formulation, development, and manufacturing services for the oral dose forms comprising p...
14 Schoolhouse Road
Somerset, NJ 08873
Key Executives for Catalent Pharma Solutions, Inc.
Chief Executive Officer, President and Director
Chief Financial Officer, Principal Accounting Officer and Executive Vice President
Senior Vice President of Global Operations
Group President for Development & Clinical Services Segment and Chief Executive Officer for Development & Clinical Services Segment
President of Oral Technologies - Modified Release Technology
Compensation as of Fiscal Year 2014.
Catalent Pharma Solutions, Inc. Key Developments
Catalent Pharma Solutions Expands Manufacturing Facility in Winchester, Kentucky
Apr 24 15
Catalent Pharma Solutions has expanded its manufacturing facility in Winchester, Kentucky. The expansion has seen the doubling of its footprint to 180,000sq.ft. The expansion features newly installed fluid bed capacity, expanded analytical laboratories, and an advanced, open facility design that provides flexibility in supporting the requirements of new customer programs. The expansion was completed in response to increased customer demand for the manufacture of complex, oral solid formulations.
Biohaven Pharmaceutical Holding Company Limited Enters into Exclusive Formulation Agreement and Global License with Catalent for Lead Product
Mar 24 15
Portage Biotech Inc. announced that Biohaven Pharmaceutical Holding Company Limited has entered into an exclusive world-wide agreement with Catalent Pharma Solutions to provide Catalent's Zydis® Orally Disintegrating Tablet (ODT) technology for Biohaven's lead drug development candidate, BHV-0223. Catalent's proprietary Zydis® technology is a unique, freeze-dried, oral solid dosage form that disperses instantly in the mouth - no water is required. Catalent has been working with Biohaven over the last six months to optimize Biohaven's formulation of BHV-0223 utilizing Zydis® ODT. Prototype development has been completed and manufacturing of clinical drug supplies is being initiated to support the formal IND filing for BHV-0223 as well as initiation of a pharmacokinetic study.
Catalent Pharma Solutions Names Sharon Johnson as New Head of Quality, Product Development and Regulatory Affairs Organization
Mar 18 15
Catalent Pharma Solutions has named Sharon Johnson, currently senior vice president of global quality and regulatory affairs, as head of its newly formed quality, product development and regulatory affairs organization. Ms. Johnson will oversee a global function that includes more than 1,500 scientists, quality professionals and regulatory affairs experts. Prior to assuming her new responsibilities, Ms. Johnson had served as Catalent's Senior vice president, Global Quality & Regulatory Affairs since 2009, having overseen the roll-out of Catalent's Global Quality Management system to over 20 global sites.
Similar Private Companies By Industry
Recent Private Companies Transactions